Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
Status:
Completed
Trial end date:
2020-10-23
Target enrollment:
Participant gender:
Summary
The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable
advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.